ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "osteoporosis"

  • Abstract Number: 2011 • ACR Convergence 2023

    Predicting Fractures in Patients with Isolated Lumbar Spine Osteoporosis Compared to Those with Isolated Hip Osteoporosis

    Nicholas Rossi1, Aamir Saeed2, Aqib Khan3, Hamzah Amin2, Ummaz Nadeem2, Zain Sultan3 and Marwan Bukhari2, 1University Hospitals of Morecambe Bay Foundation Trust, Worksop, United Kingdom, 2Lancaster University, Lancaster, United Kingdom, 3University Hospitals of Morecambe Bay Foundation Trust, Lancaster, United Kingdom

    Background/Purpose: Osteoporosis (OP) presents with fragility fractures, which can cause significant disability and cost to health services globally. There has been extensive research looking at…
  • Abstract Number: 2532 • ACR Convergence 2023

    Prevalence and Disease-Specific Factors Associated with Osteoporosis in Systemic Sclerosis: A Cross-Sectional Analysis of Two Large European Cohorts

    Charles MIDOL1, Edgar Wiebe2, Elise Siegert3, Dörte Huscher4, Helene Behal5, David Launay6, Eric Hachulla7, Eric Matteson8, Vincent Sobanski9 and Frank Buttgereit2, 1Lille University Hospital, Besançon, France, 2Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, 3Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, 4Institute of Biometry and Clinical Epidemiology and Berlin Institute of Health, Charité Universitätsmedizin Berlin, Berlin, Germany, 5Univ. Lille, CHU Lille, Biostatistics Department, Lille, France, 6Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, Lille, France, 7CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, 8Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, 9Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France

    Background/Purpose: Patients with systemic sclerosis (SSc) are at increased risk for osteoporosis (OP) and associated fragility fractures. However, the risks factors and mechanisms driving bone…
  • Abstract Number: 1867 • ACR Convergence 2023

    Peripheral Volumetric Bone Mineral Density and Erosive Disease in Patients with Established Rheumatoid Arthritis: A Cross-Sectional Study Using High-Resolution Peripheral Quantitative Computed Tomography

    Mathias Hänel1, Rasmus Klose-Jensen2, Josephine Therkildsen3, Anne-Birgitte Garm Blavnsfeldt3, Bente Langdahl3, Stinus Gadegaard Hansen4, Kresten Keller5 and Ellen Margrethe Hauge3, 1Rheumatollogy, Aarhus University Hospital, Aarhus, Denmark, 2Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 3Aarhus University Hospital, Aarhus, Denmark, 4Odense University Hospital, Svendborg Sygehus, Svendborg, Denmark, 5Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

    Background/Purpose: High resolution peripheral quantitative computed tomography (HR-pQCT) is a promising imaging modality for assessing volumetric bone mineral density (BMD) in rheumatoid arthritis (RA), and…
  • Abstract Number: 2012 • ACR Convergence 2023

    Incidence of Hyperparathyroidism in Patients with Osteoporosis Treated with Zoledronic Acid or Denosumab

    Carmen Riesco Barcena1, Jose Ivorra Cortes2, Elena Grau Garcia2, Samuel Leal Rodriguez2, Luis Gonzalez Puig2, Anderson Victor Huaylla Quispe2, Pablo Francisco Muñoz Martínez3, Alba Maria Torrat Noves2, Daniel Ramos Castro2, Laura Mas Sanchez4, Ines Canovas Olmos2, Hikmat Charia2, Isabel Martinez Cordellat2, Carmen Najera Herranz2, Rosa Negueroles Albuixech2, Jose Eloy Oller Rodriguez2, Marta De la Rubia Navarro4, Ernesto Tovar Sugrañes2, Elvira Vicens Bernabeu2, Iago Alcantara Alvarez2, Belen Villanueva Mañez2 and Jose Andres Roman Ivorra5, 1Hospital Universitario y Politécnico La Fe, Valencia, Spain, 2Rheumatology Department. HUP La Fe, Valencia, Spain, 3Rheumatology Department. HUP La Fe, Sagunto, Spain, 4Rheumatology Department. HUP La Fe, Valéncia, Spain, 5Hospital Universitari i Politècnic la Fe, Valencia, Spain

    Background/Purpose: Denosumab and Zoledronic acid are antiresorptive drugs commonly used in the treatment of osteoporosis (OP). Zoledronic acid is a third-generation bisphosphonate that inhibits osteoclastic…
  • Abstract Number: L01 • ACR Convergence 2022

    Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study

    Giovanni Adami, Angelo Fassio, Davide Bertelle, Camilla Benini, Davide Gatti and Maurizio Rossini, Rheumatology Unit, University of Verona, Verona, Italy

    Background/Purpose: The recently published GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) trial has opened the debate around the benefits of glucocorticoids (GCs) in older patients with…
  • Abstract Number: L11 • ACR Convergence 2022

    Romosozumab versus Denosumab in High-risk Patients with Glucocorticoid-induced Osteoporosis: A Pilot Randomized Controlled Trial

    Wai Han Ma1, Chi Chiu Mok2, Ling Yin Ho2, Kar Li Chan3, Sau Mei Tse4 and Sammy Chen5, 1Department of Nuclear Medicine, Hong Kong, Hong Kong, 2Tuen Mun Hospital, Hong Kong, Hong Kong, 3Tuen Mun Hospital, Tsing Yi, Hong Kong, 4Department of Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 5Department of Pathology, Hong Kong, Hong Kong

    Background/Purpose: To compare the efficacy and safety of romozosumab (ROMO) and denosumab (DEN) in high-risk patients with glucocorticoid -induced osteoporosis (GIOP)Methods: Adult patients (≥18 years)…
  • Abstract Number: 1306 • ACR Convergence 2022

    Improving Osteoporosis Screening in Individuals of Color

    Megan Brochu1, Kristofer Marcus1, Sarah Latorre1, Francis Wanjau1, Arvin Garg2, Eric Alper2, Rulan Lyu1, Tracey Wilkie1 and Jonathan Cheah3, 1UMass Memorial Health, Worcester, MA, 2UMass Memorial Health, UMass Chan Medical School, Worcester, MA, 3UMass Chan Medical School, Worcester, MA

    Background/Purpose: Osteoporosis, including the clinical event of fragility fracture is an ever-increasing public health burden. Effective screening techniques and well as therapies to reduce future…
  • Abstract Number: 1326 • ACR Convergence 2022

    Impact of COVID-19 Severity on Bone Mineral Density, Sarcopenia and Physical Performance Among Older Adults Following Hospitalization: A Pilot Study

    Diego Cabrera1, Clara Wong2, Andrew Cohen3, Lauren Ferrante3, Alexandra Hajduk3 and Evelyn Hsieh1, 1Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, New Haven, CT, 2Yale School of Public Health, New Haven, CT, 3Yale School of Medicine, New Haven, CT

    Background/Purpose: Altered bone mineral density (BMD), muscle mass and physical performance has been associated with adverse outcomes, however, the effect of COVID-19 on the musculoskeletal…
  • Abstract Number: 1307 • ACR Convergence 2022

    Effect of Romosozumab in Postmenopausal Women with Knee Osteoarthritis: Results from the FRAME Clinical Trial

    Nancy Lane1, Donald Betah2, Cynthia Deignan2, Mary Oates2, Zhenxun Wang2, Jen Timoshenko3, Aliya Khan4 and Neil Binkley5, 1University of California Davis, Hillsborough, CA, 2Amgen, Inc., Thousand Oaks, CA, 3UCB Pharma, Slough, United Kingdom, 4McMaster University, Oakville, ON, Canada, 5University of Wisconsin, Madison, WI

    Background/Purpose: Osteoarthritis (OA) and osteoporosis (OP) often occur concomitantly in the elderly. The relationship between OA and OP is complex, with increased fracture risk reported…
  • Abstract Number: 1327 • ACR Convergence 2022

    Immune Cell Subsets and Risk of Incident Hip Fracture in Older Adults: The Cardiovascular Health Study

    Rachel Elam1, Petra Buzkova2, Joseph Delaney3, Howard Fink4, Joshua Barzilay5, Laura Carbone1, Rick Saha1, John Robbins6, Kenneth Mukamal7, Rodrigo Valderrabano8, Bruce Psaty2, Russell Tracy9, Nels Olson9, Sally Huber10, Margaret Doyle9, Alan Landay11 and Jane Cauley12, 1Augusta University, Augusta, GA, 2University of Washington, Seattle, WA, 3University of Manitoba, Winnipeg, MB, Canada, 4University of Minnesota, Minneapolis, MN, 5Kaiser Permanente, Atlanta, GA, 6UC Davis, Davis, CA, 7Beth Israel Deaconess Medical Center, Boston, MA, 8Brigham and Women's Hospital, Boston, MA, 9University of Vermont, Burlington, VT, 10University of Vermont, Burlingon, VT, 11Rush University Medical Center, Chicago, IL, 12University of Pittsburgh, PIttsburgh, PA

    Background/Purpose: Cell-mediated immunity may play a role in osteoporosis development. Fracture is the major consequence of osteoporosis. Thus, cell-mediated immunity may impact fracture risk. We…
  • Abstract Number: 1308 • ACR Convergence 2022

    Prevalence and Therapeutic Practices of Osteoporosis in Sarcoidosis in the United States: A Nationwide Registry Study

    Diala Alawneh1, Moustafa Younis2, Romesa Hassan1, Bashar Alzghoul2, Shiva Arami1, Tricha Shivas3, Mary McGowan3, Khaldoon Alawneh4, Christian Ascoli1 and Nadera Sweiss1, 1University of Illinois at Chicago, Chicago, IL, 2University of Florida, Gainesville, FL, 3Foundation for Sarcoidosis Research, Chicago, IL, 4Jordan University of Science and Technology, Irbid, Jordan

    Background/Purpose: Patients with sarcoidosis are at an increased risk of developing osteoporosis due to the active inflammatory state and chronic corticosteroid use. Proper dosing of…
  • Abstract Number: 1328 • ACR Convergence 2022

    CT Evaluation of Bone Fragility 2 Years After Bariatric Surgery in Patients with Obesity: An Observational Study

    Marine FAUNY1, Marion Halin2, Edem Allado2, Didier Quilliot2, Laurent Brunaud2, Eliane Albuisson2, Isabelle Chary-Valckenaere2 and Damien Loeuille2, 1Nancy University Hospital, Toul, France, 2Nancy University Hospital, Vandoeuvre, France

    Background/Purpose: The objectives were to evaluate bone fragility on computed tomography (CT) in patients with obesity before and 2 years after bariatric surgery and to…
  • Abstract Number: 0262 • ACR Convergence 2022

    Predictors of Fragility Fracture Amongst Patients with Rheumatoid Arthritis: An Observational Cohort Study

    Seema Sharma1 and Marwan Bukhari2, 1Lancaster Royal Infirmary, Lancaster, United Kingdom, 2University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom

    Background/Purpose: Rheumatoid arthritis (RA) is associated with reduced bone mineral density and almost one third of this population have osteoporosis leading to increased risk of…
  • Abstract Number: 1309 • ACR Convergence 2022

    Evaluation of Preference and Efficacy in the Treatment of Glucocorticoid-induced Osteoporosis in Patients with Autoimmune Diseases Receiving Zoledronic Acid

    Ji-Won Kim1, Ju-Yang Jung1, Hyoun-Ah Kim1 and Chang-Hee Suh2, 1Ajou University School of Medicine, Suwon, Republic of Korea, 2Ajou University Hospital, Suwon, Republic of Korea

    Background/Purpose: The most commonly used drugs for glucocorticoid-induced osteoporosis (GIOP) is bisphosphonates, which include oral alendronate and risedronate, and intravenous zoledronic acid. Among them, zoledronic…
  • Abstract Number: 1329 • ACR Convergence 2022

    Prevalence of Bone Fragility on DXA and CT in Patients with Obesity

    Marion Halin1, Edem Allado1, Didier Quilliot1, Eliane Albuisson1, Isabelle Chary-Valckenaere1, Damien Loeuille1, Laurent Brunaud1 and Marine FAUNY2, 1Nancy University Hospital, Vandoeuvre, France, 2Nancy University Hospital, Toul, France

    Background/Purpose: Primary objective was to evaluate bone fragility prevalence on dual X-ray absorptiometry (DXA) and on computed tomography (CT), in patients with severe obesity. Secondary…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology